Addition of immune therapy 'shows promise' in gastric cancer
But two trials of first-line therapy have differing overall survival outcomes
AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.
Two trials of nivolumab plus chemotherapy versus chemotherapy show improvements in progression-free survival (PFS) for patients with advanced gastric cancer, but they have differing findings for overall survival (OS).
Both trials (CheckMate-649 and ATTRACTION-4) were reported to delegates at the European Society for Medical Oncology (ESMO) virtual congress 2020.
Reporting on a prespecified
